4CMenB
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00962624 | Jul 2010 → Mar 2011 | meningococcal meningitis | Public Health England | Completed | No outcome recorded |
| Phase 2 | NCT01027351 | Jan → Sep 2010 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00560313 | Jul 2007 → Nov 2009 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 36 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT04415424 | Jul 2021 → Jun 2025 overdue | gonorrhea | Kirby Institute | Active not recruiting | Missed primary |
| Phase 3 | NCT01973218 | Nov 2013 → Apr 2014 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01717638 | Nov 2012 → Sep 2013 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01423084 | Aug → Dec 2011 | meningococcal meningitis | Novartis | Completed | Met primary |
| Phase 3 | NCT00847145 | Feb 2009 → Aug 2010 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00657709 | Mar 2008 → Jan 2010 | meningococcal meningitis | Novartis Vaccines | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT03125616 | Aug 2017 → Sep 2019 | meningococcal infection | St George's, University of London | Completed | Mixed |
| Phase 4 | NCT02080559 | Jul 2014 → Jun 2016 | meningitis | University of Oxford | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04297436 | May 2021 → Feb 2022 | gonorrhea | University of Oxford | Completed | No outcome recorded |
| — | NCT02398396 | Apr → Nov 2015 | meningococcal infection | University of Oxford | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01272180 Comparator | Aug → Oct 2011 | meningococcal infection | Novartis Vaccines | Completed | Met primary |
| Phase 4 | NCT03089086 Comparator | Apr 2017 → Jul 2018 | meningococcal infection | University of Adelaide | Completed | No outcome recorded |
Press releases naming this drug 5 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4CMenB | “Here, we measured total IgG antibody binding profiles to a dedicated antigen microarray using human sera from an open-label Phase II trial (NCT00962624) of 4CMenB (Bexsero), a...” PMID 40043411 ↗ Mar 202513“We assessed lot-to-lot consistency, safety and immunogenicity, and the effect of concomitant vaccination on responses to routine vaccines of an investigational multicomponent...” PMID 23324563 ↗ Mar 2013 “One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12-23 months, with a booster dose 12-24...” PMID 29038320 ↗ Oct 2017 “participants 10-25 years of age received 1 booster dose of MenABCWY vaccine at 24 months (M) postprimary series of MenABCWY (2 doses), 4CMenB (2 doses) or MenACWY-CRM vaccine (1 dose).” PMID 29329168 ↗ May 2018 “The multicomponent serogroup B meningococcal (4CMenB) vaccine induces antibodies against indicator strains of serogroup B meningococcus under various schedules.” PMID 25802309 ↗ Mar 2015 “Recently, a four-component recombinant vaccine (4CMenB) has been developed and is now approved in Europe, Canada, Australia and some Latin American countries.” PMID 26232542 ↗ Jul 2015 “assessed the immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in healthy Korean adolescents.” PMID 26826544 ↗ Jan 2016 |
| Known as | 4CMenB Vaccine | “Biological: 4CMenB Vaccine” NCT03125616 ↗ |
| Known as | Bexsero | “This study will investigate the breadth of protective activity of serum anti-FHbp antibody responses of adults immunized with 4CMenB (Bexsero®) vaccine as well as investigating...” NCT02398396 ↗3“Here, we measured total IgG antibody binding profiles to a dedicated antigen microarray using human sera from an open-label Phase II trial (NCT00962624) of 4CMenB (Bexsero), a...” PMID 40043411 ↗ Mar 2025 “The 4CMenB vaccine (Bexsero®) induces antibodies in humans that recognise gonococcal proteins.” NCT04297436 ↗ “Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men” NCT04415424 ↗ |
| Known as | four component meningococcal B | “This multicomponent vaccine is also referred to as the "four component meningococcal B" or "4CMenB" vaccine.” NCT02398396 ↗ |
| Modality | Vaccine | “4CMenB is a multi-component vaccine against MenB” PMID 33020485 ↗ Oct 2020 |
| Route | Intramuscular | “0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose” NCT01717638 ↗ |